UniProt Q08499
cAMP-specific 3',5'-cyclic phosphodiesterase 4D (Q08499)
cAMP-specific 3',5'-cyclic phosphodiesterase 4D (UniProt Q08499), EC 3.1.4.53: 176 experimental structures on GenesisL1, 72 ligands bound, 198 pockets. Binding sites, pockets, druggability and 3D structures in GL1X.
- UniProt
- Q08499
- Protein
- cAMP-specific 3',5'-cyclic phosphodiesterase 4D
- EC
- 3.1.4.53
- Experimental structures
- 176
- Predicted models
- 0
- Ligands
- 72
- Pockets
- 198 · 24 records with a druggable one
Structures
176 records of Q08499 in the MolNFT archive: 176 experimental, 0 predicted.
| Entry | Title | Method | Chains | Ligands | Pockets |
|---|---|---|---|---|---|
| 1E9K | The structure of the RACK1 interaction sites located within the unique N-terminal region of the… | solution nmr | A | — | — |
| 1E9K | The structure of the RACK1 interaction sites located within the unique N-terminal region of the… | solution nmr | A | — | — |
| 1MKD | crystal structure of PDE4D catalytic domain and zardaverine complex | x-ray diffraction | A, B, C, D, E, F, G, H, I, J, K, L | — | — |
| 1MKD | Crystal structure of PDE4D catalytic domain and zardaverine complex | x-ray diffraction | A, B, C, D, E, F, G, H, I, J, K, L | — | — |
| 1OYN | Crystal structure of PDE4D2 in complex with (R,S)-rolipram | x-ray diffraction | A, B, C, D | — | — |
| 1OYN | Crystal structure of PDE4D2 in complex with (R,S)-rolipram | x-ray diffraction | A, B, C, D | — | — |
| 1PTW | The Crystal Structure of AMP-Bound PDE4 Suggests a Mechanism for Phosphodiesterase Catalysis | x-ray diffraction | A, B, C, D | — | — |
| 1PTW | The crystal structure of AMP-bound PDE4 suggests a mechanism for phosphodiesterase catalysis | x-ray diffraction | A, B, C, D | — | — |
| 1Q9M | Three dimensional structures of PDE4D in complex with roliprams and implication on inhibitor… | x-ray diffraction | A, B, C, D | — | — |
| 1Q9M | Three dimensional structures of PDE4D in complex with roliprams and implication on inhibitor… | x-ray diffraction | A, B, C, D | — | — |
| 1TB7 | Catalytic Domain Of Human Phosphodiesterase 4D In Complex With AMP | x-ray diffraction | A, B | — | — |
| 1TB7 | Catalytic domain of human phosphodiesterase 4D in complex with AMP | x-ray diffraction | A, B | — | — |
| 1TBB | Catalytic Domain Of Human Phosphodiesterase 4D In Complex With Rolipram | x-ray diffraction | A, B | — | — |
| 1TBB | Catalytic domain of human phosphodiesterase 4D in complex with rolipram | x-ray diffraction | A, B | — | — |
| 1XOM | Catalytic Domain Of Human Phosphodiesterase 4D In Complex With Cilomilast | x-ray diffraction | A, B | — | — |
| 1XOM | Catalytic domain of human phosphodiesterase 4D in complex with cilomilast | x-ray diffraction | A, B | — | — |
| 1XON | Catalytic Domain Of Human Phosphodiesterase 4D In Complex With Piclamilast | x-ray diffraction | A, B | — | — |
| 1XON | Catalytic domain of human phosphodiesterase 4D in complex with piclamilast | x-ray diffraction | A, B | — | — |
| 1XOQ | Catalytic Domain Of Human Phosphodiesterase 4D In Complex With Roflumilast | x-ray diffraction | A, B | — | — |
| 1XOQ | Catalytic domain of human phosphodiesterase 4D in complex with roflumilast | x-ray diffraction | A, B | — | — |
| 1XOR | Catalytic Domain Of Human Phosphodiesterase 4D In Complex With Zardaverine | x-ray diffraction | A, B | — | — |
| 1XOR | Catalytic domain of human phosphodiesterase 4D in complex with zardaverine | x-ray diffraction | A, B | — | — |
| 1Y2B | Catalytic Domain Of Human Phosphodiesterase 4D In Complex With… | x-ray diffraction | A, B | — | — |
| 1Y2B | Catalytic domain of human phosphodiesterase 4D in complex with 3,5… | x-ray diffraction | A, B | — | — |
| 1Y2C | Catalytic Domain Of Human Phosphodiesterase 4D In Complex With… | x-ray diffraction | A, B | — | — |
| 1Y2C | Catalytic domain of human phosphodiesterase 4D in complex with 3,5… | x-ray diffraction | A, B | — | — |
| 1Y2D | Catalytic Domain Of Human Phosphodiesterase 4D In Complex With… | x-ray diffraction | A, B | — | — |
| 1Y2D | Catalytic domain of human phosphodiesterase 4D in complex with 1-(4… | x-ray diffraction | A, B | — | — |
| 1Y2E | Catalytic Domain Of Human Phosphodiesterase 4D In Complex With… | x-ray diffraction | A, B | — | — |
| 1Y2E | Catalytic domain of human phosphodiesterase 4D in complex with 1-(4… | x-ray diffraction | A, B | — | — |
| 1Y2K | Catalytic Domain Of Human Phosphodiesterase 4D In Complex With… | x-ray diffraction | A, B | — | — |
| 1Y2K | Catalytic domain of human phosphodiesterase 4D in complex with 3,5… | x-ray diffraction | A, B | — | — |
| 1ZKN | Structure of PDE4D2-IBMX | x-ray diffraction | A, B, C, D | — | — |
| 1ZKN | Structure of PDE4D2-ibmx | x-ray diffraction | A, B, C, D | — | — |
| 2FM0 | Crystal structure of PDE4D in complex with L-869298 | x-ray diffraction | A, B, C, D | — | — |
| 2FM0 | Crystal structure of PDE4D in complex with L-869298 | x-ray diffraction | A, B, C, D | — | — |
| 2FM5 | Crystal structure of PDE4D2 in complex with inhibitor L-869299 | x-ray diffraction | A, B, C, D | — | — |
| 2FM5 | Crystal structure of PDE4D2 in complex with inhibitor L- 869299 | x-ray diffraction | A, B, C, D | — | — |
| 2PW3 | Structure of the PDE4D-cAMP complex | x-ray diffraction | A, B | — | — |
| 2PW3 | Structure of the PDE4D-camp complex | x-ray diffraction | A, B | — | — |
| 2QYN | Crystal structure of PDE4D2 in complex with inhibitor NPV | x-ray diffraction | A, B | — | — |
| 2QYN | Crystal structure of PDE4D2 in complex with inhibitor npv | x-ray diffraction | A, B | — | — |
| 3G4G | Crystal structure of human phosphodiesterase 4d with regulatory domain and d155871 | x-ray diffraction | A, B, C, D | — | — |
| 3G4G | Crystal structure of human phosphodiesterase 4D with regulatory domain and D155871 | x-ray diffraction | A, B, C, D | — | — |
| 3G4I | Crystal structure of human phosphodiesterase 4d with d155871 | x-ray diffraction | A, B, C, D | — | — |
| 3G4I | Crystal structure of human phosphodiesterase 4D with D155871 | x-ray diffraction | A, B, C, D | — | — |
| 3G4K | Crystal structure of human phosphodiesterase 4d with rolipram | x-ray diffraction | A, B, C, D | — | — |
| 3G4K | Crystal structure of human phosphodiesterase 4D with rolipram | x-ray diffraction | A, B, C, D | — | — |
| 3G4L | Crystal structure of human phosphodiesterase 4d with roflumilast | x-ray diffraction | A, B, C, D | — | — |
| 3G4L | Crystal structure of human phosphodiesterase 4D with roflumilast | x-ray diffraction | A, B, C, D | — | — |
| 3G58 | Crystal structure of human phosphodiesterase 4d with d155988/pmnpq | x-ray diffraction | A, B, C, D | — | — |
| 3G58 | Crystal structure of human phosphodiesterase 4D with D155988/PMNPQ | x-ray diffraction | A, B, C, D | — | — |
| 3IAD | Crystal structure of human phosphodiesterase 4D with bound allosteric modulator | x-ray diffraction | A, B, C, D | — | — |
| 3IAD | Crystal structure of human phosphodiesterase 4D with bound allosteric modulator | x-ray diffraction | A, B, C, D | — | — |
| 3IAK | Crystal structure of human phosphodiesterase 4d (PDE4d) with papaverine. | x-ray diffraction | A | — | — |
| 3IAK | Crystal structure of human phosphodiesterase 4D (PDE4D) with papaverine. | x-ray diffraction | A | — | — |
| 3K4S | The structure of the catalytic domain of human PDE4d with… | x-ray diffraction | A | — | — |
| 3K4S | The structure of the catalytic domain of human PDE4D with 4… | x-ray diffraction | A | — | — |
| 3SL3 | Crystal structure of the apo form of the catalytic domain of PDE4D2 | x-ray diffraction | A, B, C, D | — | — |
| 3SL3 | Crystal structure of the apo form of the catalytic domain of PDE4D2 | x-ray diffraction | A, B, C, D | — | — |
116 records more on the page itself.
Ligands
- ZN · Zinc ion · in 99 records
- MG · Magnesium ion · in 98 records
- AKU · (1S)-1-[2-(1H-indol-3-yl)ethyl]-6,7-dimethoxy-3,4-dihydroisoquinoline-2(1H)-carbaldehyde · in 3 records
- SO4 · Sulfate ion · in 3 records
- 1AS · (~{E})-4-[9-[(4-fluorophenyl)methoxy]-8-methoxy-2,2-dimethyl-7-(3-methylbut-2-enyl)-6-oxidanylidene-pyrano[3,2-b]xanthen-5-yl]oxybut-2-enoic acid · in 2 records
- 4I7 · (4~{A}~{S},8~{A}~{R})-4-[4-methoxy-3-[[2-(trifluoromethyl)phenyl]methoxy]phenyl]-2-(1-thieno[3, 2-d]pyrimidin-4-ylpiperidin-4-yl)-4~{A},5,8,8~{A}-tetrahydrophthalazin-1-one · in 2 records
- 6M5 · (4~{A}~{S},8~{A}~{R})-2-cycloheptyl-4-[4-methoxy-3-[4-[4-(1~{H}-1,2,3,4-tetrazol-5-yl) phenoxy]butoxy]phenyl]-4~{A},5,8,8~{A}-tetrahydrophthalazin-1-one · in 2 records
- 6PT · 4-[(5-acetyl-2-ethyl-3-oxo-6-phenyl-2,3-dihydropyridazin-4-yl)amino]benzoic acid · in 2 records
- 6Q2 · 4-[(3-methoxyphenyl)amino]-2-phenyl-7,8-dihydro-1,6-naphthyridin-5(6H)-one · in 2 records
- AH9 · 6,7-dimethoxy-3,4-dihydroisoquinoline-2(1H)-carbaldehyde · in 2 records
- AK0 · (1S)-1-[2-(6-fluoro-1H-indol-3-yl)ethyl]-6,7-dimethoxy-3,4-dihydroisoquinoline-2(1H)-carbaldehyde · in 2 records
- CL · Chloride ion · in 2 records
- CV8 · 2-[(~{E})-(3-cyclopentyloxy-4-methoxy-phenyl) methylideneamino]oxy-1-[(2~{R},6~{S})-2,6-dimethylmorpholin-4-yl]ethanone · in 2 records
- CZK · (2~{S})-1-[3-(3-cyclopentyloxy-4-methoxy-phenyl) pyrazol-1-yl]-3-morpholin-4-yl-propan-2-ol · in 2 records
- CZQ · 2-[(~{E})-[4-[bis(fluoranyl)methoxy]-3-cyclopentyloxy-phenyl]methylideneamino]oxy-1-[(2~{R},6~{R})-2,6-dimethylmorpholin-4-yl]ethanone · in 2 records
- CZT · (2~{R})-1-[(~{E})-(3-cyclopentyloxy-4-methoxy-phenyl) methylideneamino]oxy-3-[(2~{R},6~{S})-2,6-dimethylmorpholin-4-yl]propan-2-ol · in 2 records
- D0B · 3-[3-(3-cyclopentyloxy-4-methoxy-phenyl)pyrazol-1-yl]-1-[(2~{R},6~{R})-2,6-dimethylmorpholin-4-yl]propan-1-one · in 2 records
- D0E · 3-[3-(3-cyclopentyloxy-4-methoxy-phenyl)pyrazol-1-yl]-1-morpholin-4-yl-propan-1-one · in 2 records
- D5N · (2~{S})-1-[5-[4-[bis(fluoranyl)methoxy]-3-cyclopentyloxy-phenyl]pyrazol-1-yl]-3-morpholin-4-yl-propan-2-ol · in 2 records
- D5Z · (4aS,8aR)-2-[1-(2-aminoquinazolin-4-yl)piperidin-4-yl]-4-(3,4-dimethoxyphenyl)-1,2,4a,5,8,8a-hexahydrophthalazin-1-one · in 2 records
- DD5 · (2~{R})-1-[3-[4-[bis(fluoranyl)methoxy]-3-cyclopentyloxy-phenyl]pyrazol-1-yl]-3-morpholin-4-yl-propan-2-ol · in 2 records
- E31 · 2-(4-{[2-(3-chlorophenyl)-6-ethylpyrimidin-4-yl]methyl}phenyl)acetamide · in 2 records
- E3Q · 1-cycloheptyl-3-{4-methoxy-3-[(2-methoxyphenyl) methoxy]phenyl}-4,4-dimethyl-4,5-dihydro- 1H-pyrazol-5-one · in 2 records
- E6E · 4-{4-methoxy-3-[(2-methoxyphenyl)methoxy]phenyl}-2-(1-{thieno[3,2-d]pyrimidin-4-yl}piperidin-4-yl)-1,2,4A,5, 8,8A-hexahydrophthalazin-1-one · in 2 records
- E6N · (4~{A}~{S},8~{A}~{S})-4-[4-methoxy-3-[(2-methoxyphenyl)methoxy]phenyl]-2-[1-(3-nitroimidazo[1, 2-b]pyridazin-6-yl)piperidin-4-yl]-4~{A},5,6,7,8, 8~{A}-hexahydrophthalazin-1-one · in 2 records
- EQC · Arctigenin · in 2 records
- FFZ · 3-[5-[(4ar,8as)-4-oxidanylidene-3-propan-2-yl-4A,5,8, 8A-tetrahydrophthalazin-1-yl]-2-methoxy-phenyl]-N-(phenylmethyl)prop-2-ynamide · in 2 records
- FTX · (1S)-1-[(7-chloranyl-1H-indol-3-yl)methyl]-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-2-carbaldehyde · in 2 records
- J20 · 1-[2-(4-hydroxyphenyl)ethynyl]-9,9-bis(4-methoxyphenyl)-7-oxidanyl-fluorene-2-carbaldehyde · in 2 records
- JX2 · 3-[5-[(4~{a}~{R},8~{a}~{S})-3-cycloheptyl-4-oxidanylidene-4~{a},5,8,8~{a}-tetrahydrophthalazin-1-yl]-2-methoxy-phenyl]-~{N}-(furan-2-ylmethyl)prop-2-ynamide · in 2 records
Elsewhere
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.